Mycophenolic Acid Exposure Determines Antibody Formation Following SARS‐CoV‐2 Vaccination in Kidney Transplant Recipients: A Nested Cohort Study
Authors:
- Soufian MeziyerhSMSoufian Meziyerh
- Pim BouwmansPBPim Bouwmans
- Teun van GelderTGTeun van Gelder
- Danny van der HelmDHDanny van der Helm
- Lianne MesschendorpLMLianne Messchendorp
- Paul J. M. van der BoogPBPaul J. M. van der Boog
- Johan W. de FijterJFJohan W. de Fijter
- Dirk Jan A. R. MoesDirk Jan A. R. Moes
- Aiko P. J. de VriesAVAiko P. J. de Vries
- Recovac CollaboratorsRCRecovac Collaborators
Open Access
- 14 March 2023
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 114 (1) , 118-126
Abstract
Despite (repeated) boosting, kidney transplant recipients (KTRs) may remain at increased risk of severe COVID‐19 since a substantial number of individuals remain seronegative or with low antibody titers. In particular, mycophenolic acid use has been shown to affect antibody formation negatively and may be an important modifiable risk factor. We investigated the exposure–response relationship between mycophenolic acid 12‐hour area under the curve (AUC0–12h) exposure and seroconversion including antibody titers after vaccination using mRNA‐1273 SARS‐CoV‐2 vaccine (Moderna) in 316 KTRs from our center that participated in the national Dutch renal patients COVID‐19 vaccination – long term efficacy and safety of SARS‐CoV‐2 vaccination in kidney disease patients vaccination study. After two vaccination doses, 162 (51%) KTRs seroconverted. KTRs treated with mycophenolic acid showed less seroconversion and lower antibody titers compared with KTRs without mycophenolic acid (44% vs. 77%, and 36 binding antibody units (BAU)/mL vs. 340 BAU/mL; P < 0.001). The mean mycophenolic acid AUC0–12h exposure was significantly lower in KTRs who seroconverted compared with KTRs who did not (39 vs. 29 mg⋅h/L; P < 0.001). High mycophenolic acid exposure (±90 mg⋅h/L) and no exposure to mycophenolic acid resulted in a seroconversion rate ranging from 10% to 80%. Every 10 mg⋅h/L increase in mycophenolic acid AUC0–12h gave an adjusted odds ratio for seroconversion of 0.87 (95% confidence interval (CI), 0.79–0.97; P = 0.010) and 0.89 (95% CI, 0.85–0.93; P < 0.001) for KTRs on dual and triple maintenance immunosuppressive therapy, respectively. Higher mycophenolic acid AUC0–12h correlated with lower antibody titers (R = 0.44, P < 0.001). This study demonstrates the exposure–response relationship between gold standard mycophenolic acid exposure and antibody formation to support interventional studies investigating mycophenolic acid adjustment to improve antibody formation after further boosting.Keywords
This publication has 44 references indexed in Scilit:
- Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical ToxicologyTherapeutic Drug Monitoring, 2021
- COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaborationNephrology Dialysis Transplantation, 2020
- Factors associated with COVID-19-related death using OpenSAFELYNature, 2020
- Severe COVID-19 in a renal transplant recipient: A focus on pharmacokineticsAmerican Journal of Transplantation, 2020
- Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO TrialAmerican Journal of Transplantation, 2016
- Large decrease of anti-tetanus anatoxin and anti-pneumococcal antibodies at one year after renal transplantationClinical Nephrology, 2013
- Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccinationKidney International, 2012
- Mycophenolic Acid Differentially Impacts B Cell Function Depending on the Stage of DifferentiationThe Journal of Immunology, 2011
- Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposureTransplantation Reviews, 2011
- Pharmacodynamic Monitoring of Mycophenolate MofetilClinical Chemistry and Laboratory Medicine (CCLM), 2000